New Gout Treatment Guidelines Emphasize Genetic Risk, Need for Medications

Gout, a profoundly painful form of inflammatory arthritis, affects approximately four percent of adults across the United States, according to the Arthritis Foundation. Characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in the joints, it most commonly strikes the big toe but can also affect other joints in the foot, ankle, and knee. This condition arises from an accumulation of uric acid crystals in the joints, leading to intense inflammation. Notably, men are three times more susceptible to gout than women, highlighting a significant demographic disparity in its prevalence.

In a pivotal development for gout management, the American College of Rheumatology (ACR) released updated guidelines for gout treatment in May 2020. This comprehensive update, the first since 2012, integrates the latest clinical research and refined expert consensus to enhance patient care. These new recommendations underscore an evolving understanding of gout, moving beyond traditional perceptions to incorporate advanced insights into its genetic underpinnings and the critical role of timely pharmacological interventions. The updated guideline was published online in Arthritis Care & Research on May 11, 2020, providing a robust framework for clinicians.

Why Update the Gout Care Guideline Now?

The decision by the ACR to revise its gout treatment guidelines stems directly from the significant advancements in clinical research over the past eight years. Since the last comprehensive update in 2012, a wealth of new scientific evidence has emerged, offering deeper insights into the pathophysiology of gout, optimal treatment strategies, and the long-term management of this complex condition. These new findings necessitated a thorough review and adjustment of existing recommendations to ensure that healthcare providers are equipped with the most current and effective approaches for treating their patients.

This updated guideline not only incorporates novel research but also reinforces the scientific foundation for many established recommendations, lending them greater authority and certainty. Dr. John FitzGerald, a distinguished rheumatologist at UCLA Medical Center in Los Angeles and a coauthor of the guideline update, emphasized this point. He noted that the new guidelines provide a "stronger level of evidence for many prior and familiar recommendations," particularly reinforcing a "treat-to-target" approach. This enhanced evidence base allows for greater confidence in clinical decisions, aiming to achieve the best possible outcomes for individuals living with gout.

Stronger Evidence Supports Existing Recommendations

The revised guidelines deliver a more robust evidence base for many long-standing clinical practices and recommendations in gout management. Dr. FitzGerald, a key figure in the guideline development, highlighted that the past eight years have seen substantial advancements in research, providing clearer scientific support for previously recognized strategies. This strengthening of evidence is particularly significant for the "treat-to-target" approach, which has been central to effective gout care.

This means that while some core principles remain consistent, the scientific backing for these principles has been significantly amplified. The updated guidelines, therefore, serve not just as a revision but as a solidification of best practices, providing clinicians with increased certainty in their treatment decisions. The goal is to move towards more predictable and successful patient outcomes by grounding treatment strategies in the most rigorous and recent scientific data available.

Treat-to-Target Protocol Emphasized

The "treat-to-target" (T2T) approach, a collaborative strategy between doctor and patient to define and achieve specific treatment goals, receives a heightened emphasis in the updated guidelines. While this protocol was part of the 2012 recommendations, its inclusion was largely based on observational data at the time. The landscape has since changed, with recent randomized controlled trials providing compelling evidence of its efficacy. These robust studies have yielded positive results, significantly reinforcing the T2T recommendation with more rigorous data.

A critical aspect of this reinforced T2T protocol is the clear articulation of a specific therapeutic goal: a serum urate level consistently below 6 milligrams per deciliter (mg/dL). This precise target provides clinicians and patients with a quantifiable objective, facilitating more proactive and effective management of gout. By striving for and maintaining this lower urate level, the T2T strategy aims to prevent the formation of new uric acid crystals, dissolve existing ones, and ultimately reduce the frequency and severity of gout flares, thereby improving long-term patient outcomes and quality of life.

Early Diagnosis Is Stressed, Especially for People With Kidney Disease and Other Comorbidities

The updated guidelines place a significant emphasis on the importance of early diagnosis and prompt treatment initiation for patients with gout. This directive is particularly crucial for individuals who present with extremely high uric acid levels or co-existing medical conditions that can exacerbate gout or complicate its management, such as kidney disease or the presence of gouty kidney stones. Recognizing and addressing gout early in these vulnerable patient populations is paramount to mitigating potential long-term complications.

Dr. Daniel Hernandez, director of medical affairs and Hispanic outreach for CreakyJoints, underscores the importance of this shift. He highlights that receiving treatment sooner can substantially reduce the risk of permanent joint damage and other systemic issues associated with uncontrolled gout. Early intervention aims to prevent the progressive accumulation of urate crystals, which can otherwise lead to chronic arthritis, joint deformity, and impaired kidney function. This proactive approach ensures better preservation of joint health and overall systemic well-being for affected individuals.

Stronger Emphasis on Early Use, Proper Dosing With Allopurinol

The updated guidelines strongly endorse allopurinol (brand name Zyloprim) as the primary first-line treatment for gout, advocating for its initiation earlier in the disease course, particularly for patients with co-existing medical conditions. This renewed emphasis builds upon its recommendation in the 2012 guidelines but provides a more definitive stance due to accumulating evidence of its effectiveness and safety profile. A key advantage of allopurinol is its cost-effectiveness, making it an accessible option for many patients.

In contrast, another common urate-lowering drug, febuxostat (brand name Uloric), has been associated with potential cardiovascular safety concerns, further solidifying allopurinol’s position as the preferred initial therapy. Dr. FitzGerald stresses the importance of cautious dosing when starting allopurinol. To minimize adverse effects such as drug rash or an acute gout flare, which can occur when initiating urate-lowering treatment, it is critical to begin with a low dose and gradually increase it. This titration process ensures that the serum urate level is slowly brought down to the desired target, thereby optimizing efficacy while mitigating potential discomfort and side effects for the patient.

Test to Limit the Risk of an Allopurinol Allergic Reaction

A crucial addition to the updated guidelines involves pre-screening for a specific genetic marker, HLA-B*5801, to mitigate the risk of a severe allergic reaction to allopurinol, known as allopurinol hypersensitivity syndrome. This potentially life-threatening drug rash underscores the importance of personalized medicine in gout treatment. In the 2012 guideline, this testing was specifically recommended for individuals of Asian descent, who are known to have a higher prevalence of this genetic marker.

Based on new clinical data and a broader understanding of genetic predispositions, the 2020 guideline expands this recommendation to include African American patients. This expansion reflects an enhanced awareness of diverse patient populations and their genetic vulnerabilities, ensuring that more individuals at risk are identified and protected before starting allopurinol therapy. Pre-emptive genetic screening allows clinicians to make informed decisions, selecting alternative treatments for those positive for the marker and thereby preventing severe adverse drug reactions.

Use Anti-Inflammatories for 3 to 6 Months When Starting Allopurinol

When initiating any urate-lowering therapy for gout, such as allopurinol, patients often experience an initial period where gout flares may temporarily increase. This phenomenon, often described by Dr. FitzGerald as the gout "getting angry" before it gets better, is a common and anticipated side effect. To effectively manage this heightened risk of flares during the treatment's onset, the new guidelines recommend a specific prophylactic strategy involving anti-inflammatory drugs.

The updated recommendation advises taking anti-inflammatory medications for a duration of three to six months when beginning urate-lowering therapy. This adjusts the previous guideline, which suggested six or more months of prophylaxis. The rationale behind this modification is rooted in the understanding that the risk of gout flares progressively diminishes after each month of treatment. Therefore, shorter, more targeted courses of anti-inflammatory prophylaxis are likely sufficient to bridge this initial vulnerable period. By carefully adhering to these guidelines, including starting with a lower allopurinol dose and using anti-inflammatory agents preventatively, the risk of side effects, including increased gout flares, can be significantly lowered, ultimately leading to greater patient adherence and more successful treatment outcomes.

No More Patient Blame Game

A significant and empathetic shift in the updated guidelines is the explicit acknowledgment that the onset of gout is not solely attributable to a patient's lifestyle or dietary choices. For the first time, the ACR has formally recognized the strong genetic determinants of gout, moving away from any implication of "patient-blaming" for the condition's development. This represents a crucial paradigm shift in the medical community's approach to understanding and communicating about gout.

As Dr. Daniel Hernandez pointed out, this recognition is vital for improving the patient experience. Historically, there has been a tendency to associate gout predominantly with dietary excesses, leading to undue stigma and self-blame among those affected. By highlighting the powerful influence of genetics, the new guidelines foster a more compassionate and accurate understanding of gout as a complex medical condition with inherent biological predispositions. This shift encourages a more supportive doctor-patient relationship, focused on evidence-based treatment and management rather than judgment, empowering patients to engage more openly and effectively in their care journey.

---

iStock
By
Beth Levine
Fact Checked
Updated on May 21, 2020

Original article: https://www.everydayhealth.com/gout/new-gout-treatment-guidelines-emphasize-genetic-risks/